Skip to content

The regulatory mechanism of the "intestines-kidney" axis in diabetic nephropathy and the intervention effect of traditional Chinese medicine on "spleen not dispersing essence toxicity damaging kidney collaterals" based on multi-omics analysis and bacterial-drug interactions.

The regulatory mechanism of the "intestines-kidney" axis in diabetic nephropathy and the intervention effect of traditional Chinese medicine on "spleen not dispersing essence toxicity damaging kidney collaterals" based on multi-omics analysis and bacterial-drug interactions.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025000820
Enrollment
Unknown
Registered
2025-04-22
Start date
2022-04-01
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy

Interventions

healthy people gourp:NA
DKD group:NA
T2DM group:NA

Sponsors

the First Affiliated Hospital of Hunan University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Age =18 years old and =75 years old gender is not limited; (2) Complete demographic data; (3) Meet the diagnostic criteria of the Chinese Guidelines for the Prevention and Treatment of Diabetic Kidney Disease (2021 edition) the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 edition) and the Guidelines for the Screening Diagnosis Prevention and Treatment of Chronic Kidney Disease (2017 edition); (4) The patient is informed of the study as approved by the ethics committee. Healthy population inclusion criteria (1) The patient has no known history of infection or risk factors including HIV hepatitis B or C virus syphilis etc. and no current systemic infection; (2) no obesity (body mass index >30) and/or diabetes no history of chronic kidney disease; Approved by the ethics committee patients were informed about the study.

Exclusion criteria

Exclusion criteria: (1) Infection or other acute disease within 1 month before this inclusion; (2) in a state of stress; (3) other unstable chronic diseases; (4) Have a history of acute and chronic gastrointestinal diseases including acute gastroenteritis functional gastrointestinal diseases inflammatory bowel disease celiac disease and other chronic gastrointestinal diseases; (5) Recent (=3 months) exposure to systemic antibiotics immunosuppressants chemotherapy history and chronic treatment history of proton pump inhibitors; (6) Pregnant or lactating women; (7) Recently (=3 months) participated in other drug clinical researchers; (8) People suffering from mental illness intellectual disability confusion etc. who cannot cooperate with the completion of relevant information collection; Subjects who met one or more of these criteria were excluded from the study.

Design outcomes

Primary

MeasureTime frame
UACR;blood urea nitrogen;serum creatinine;Uric Acid;total cholesterol;Targeted metabolomics technology detection;FBG;eGFR;HbA1c;Non-targeted metabolomics technology detection;16S rDNA test;glycated serum protein;

Secondary

MeasureTime frame
HDL-C;LDL-C;Triglyceride;

Countries

CHINA

Contacts

Public ContactRONG YU

Hunan University of Traditional Chinese Medicine

yuron@21.cn.com13755119720

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026